Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.» Read More
Biogen Idec said after markets closed Wednesday that it ended its review of strategic options after failing to receive any definitive takeover bids.
The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."
Late yesterday afternoon, the Food and Drug Administration put out what it calls an "Early Communication" announcing that it's looking into possible dangerous side effects from Pfizer's hot, new smoking cessation pill, Chantix. The company sold nearly a quarter-billion dollars worth of the drug in the third quarter which put it on track to quickly achieve billion-dollar blockbuster status.
What are the best trades when a volatile market acts like 100 squirrels in a bag?
On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".
Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.
Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.
Biotechnology company Biogen Idec, which put itself up for sale earlier this month, reported third-quarter earnings and revenue Tuesday that fell short of analysts' expectations.
Will Friday’s sell-off have a dramtaic impact on Monday's trading and the earnings flood that lies ahead?
The Big Pharma earnings season is in full swing with Pfizer (PFE), Eli Lilly (LLY) and Wyeth (WYE) out Thursday and Merck (MRK) and Schering-Plough (SGP) reporting Monday. What’s the trade as the drug companies deal with their ailing pipelines?
Also, explaining the short interest in Hologic and the "mindboggling" run in PetroChina.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks closed lower after financial giant Citigroup halted its stock buyback plan and said it and two other big U.S. banks will create a multibillion-dollar fund in order to support the struggling commercial debt market.
For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.
Genzyme said Sunday that three-year data from a mid-stage trial of its experimental multiple sclerosis drug showed it to be very effective, but patients must be monitored on a monthly basis to avoid a potentially deadly side effect.
Biogen Idec, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.
Biogen Idec, which makes the multiple sclerosis drugs Avonex and Tysabri, said onFriday that it has put itself up for sale.
Carl Icahn - his name is synonymous with American capitalism. Following is an exclusive Fast Money interview with the billionaire investor. Find out what he has to say about Bear Stearns and discover his intentions with BEA Systems plus more.
Our traders are good - but you knew that! Check out their latest picks that paid.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Will the turbulent market settle in the new season or is there more volatility ahead? What sectors are poised to gain the most this fall? The traders guide you through what is historically one of the most active times of the year for the stock market.